
<u>La Renon</u>

PIMASTILL

Pimavanserin 34 mg Capsules





Pimavanserin 34 mg Capsules


Background

Parkinson's disease (PD) is traditionally known for motor symptoms, but neuropsychiatric symptoms like psychosis, anxiety and depression also significantly affects patient's quality of life.

Over 50% of patients with Parkinson's disease develop psychosis at some point during their illness. The prevalence of psychosis in PD may range from 16% to 75%.¹

The American Academy of Neurology (AAN) quality improvement guidelines recommend that neuropsychiatric symptoms should be assessed annually in all patients with PD.²

Beyond Dopamine: The Unique Serotonin-Selective Action of Pimavanserin



Why Pimavanserin Is Better for Parkinson Disease Psychosis (PDP)?

Lower Side Effect Profile: Pimavanserin's selective action avoids dopamine blockade, reducing risks of motor symptoms side effects which is critical for Parkinson's patients.

Specialized Targeting: The 5-HT2A receptor specificity is more targeted, making it effective in Parkinson's disease psychosis without worsening Parkinsonian symptoms.

Simplicity in Dosing: Once-daily dosing at a standard level (34 mg) simplifies treatment for elderly and sensitive populations.

Clinical Evidences



Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

Reference: The Lancet. 2014 Feb 8;383(9916):533-40.

No. of Patients
199 Patients

Dose 40 mg/Day

Duration
6 Weeks

Result:

Pimavanserin is associated with a -5.79 decrease in SAPS-PD scores, compared to -2.73 for placebo.

Conclusion:

Overall, Pimavanserin is well tolerated with no significant safety concerns or worsening of motor function.



Pimavanserin in the Treatment of Parkinson's Disease Psychosis: Meta-analysis and Meta-regression of Randomized Clinical Trials

Ref: Innov Clin Neurosci. 2022 Jan-Mar;19(1-3):46-51.

No. of Patients

Meta-analysis compiling data of 680 Patients

Dose
Duration

10, 20, 40 & 60 mg
4 to 6 weeks

Result:

Treatment with Pimavanserin was associated with a significant reduction in scores using the Scale of Assessment of Positive Symptoms, Hallucinations, and Delusion.

Conclusion:

There is a significant improvement in psychosis symptoms in patients with PD who took Pimavanserin. Pimavanserin is also shown to be protective against orthostatic hypotension.



Pimavanserin 34 mg Capsules

Description


PIMASTILL consist of Pimavanserin 34 mg capsule which is an atypical antipsychotic used for hallucinations and delusions that accompany Parkinson Disease Psychosis (PDP).

Indication

For the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis.

MOA

It is a unique drug that acts as an inverse agonist of the 5HT-2A receptors, with selectivity over 5HT-2C receptors that avoids the dopamine blockade without worsening PD motor symptoms.



Salient features

- Only FDA approved drug for the treatment of PDP.
- Acceptable tolerability profile and no worsening of cognition.
- Targeting serotonin receptors & ensures better safety than other antipsychotics.
- Promising candidate for treating PDP without worsening PD motor symptoms.²

Dose

To be administered once daily or as prescribed by Registered Medical Practitioner.

Presentation

Available as a strip of 10 Capsules.

References:

1.Annals of Movement Disorders 2(3):83 2.January 2016 US Neurology 12(02):93



Scan for more prescribing information

Mail me at:

| I am: _______ | Call me on: _____

La Renon Healthcare Private Limited